Clinical medicine and the budding science of indoor mold exposure

European Journal of Internal Medicine

Volumn 18, Issue 7, 2007, Pages 516-523

  Genuis, Stephen J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Allergy; Environmental health; Fungi; Human exposure assessment; Mold; Mycotoxin

Indexed keywords

AMPHOTERICIN B; ANTIDEPRESSANT AGENT; BRONCHODILATING AGENT; MYCOTOXIN; SEDATIVE AGENT; STEROID;

ADULT; ALLERGIC DISEASE; ALLERGIC REACTION; AMBIENT AIR; ANOREXIA NERVOSA; ASPERGILLUS; ASTHMA; BLASTOMYCES; CANDIDA ALBICANS; CASE REPORT; CHRONIC SINUSITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL MEDICINE; COCCIDIOIDES; CRYPTOCOCCUS; DEPRESSION; DETOXIFICATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; FATIGUE; FEMALE; FUSARIUM; HEADACHE; HEALTH HAZARD; HISTOPLASMOSIS; HUMAN; INSOMNIA; MOULD; MYCOSIS; PATHOGENESIS; PNEUMOCYSTIS; REVIEW; RISK ASSESSMENT; SINUS CONGESTION; STACHYBOTRYS; TRICHOPHYTON;

EID: 35448933290     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.05.005     Document Type: Review

References (59)

1. Pinker S. ORs closed after Aspergillus discovered at Royal Vic. CMAJ 164 9 (2001) 1333
2. Centers for Disease Control and P. Update: pulmonary hemorrhage/hemosiderosis among infants-Cleveland, Ohio, 1993-1996. MMWR Morb Mortal Wkly Rep 46 2 (1997) 33-35
3. Taskinen T., Hyvarinen A., Meklin T., Husman T., Nevalainen A., and Korppi M. Asthma and respiratory infections in school children with special reference to moisture and mold problems in the school. Acta Paediatr 88 12 (1999) 1373-1379
4. Hampton T. Scientists plan New Orleans Mold Project. JAMA 295 23 (2006) 2710
5. Lee T.G. Health symptoms caused by molds in a courthouse. Arch Environ Health 58 7 (2003) 442-446
6. Jaakkola M.S., Nordman H., Piipari R., Uitti J., Laitinen J., Karjalainen A., et al. Indoor dampness and molds and development of adult-onset asthma: a population-based incident case-control study. Environ Health Perspect 110 5 (2002) 543-547
7. Brandt M., Brown C., Burkhart J., Burton N., Cox-Ganser J., Damon S., et al. Mold Prevention Strategies and Possible Health Effects in the Aftermath of Hurricanes and Major Floods. MMWR Recomm Rep 55 (2006) 1-27 [R0B]
8. Johanning E. Indoor moisture and mold-related health problems. Allerg Immunol (Paris) 36 5 (2004) 182-185
9. American Academy of Pediatrics - Committee on Environmental H. Toxic effects of indoor molds. Pediatrics 101 4 Pt 1 (1998) 712-714
10. Jarvis B.B. Chemistry and toxicology of molds isolated from water-damaged buildings. In: DeVries J.W., Trucksess M.W., and Jackson L.S. (Eds). Mycotoxins and Food Safety (2002), Kluwer Academic/Plenum Publishers 43-52
11. Chiu A.M., and Fink J.N. Fungal allergy and pathogenicity. Introduction. Chem Immunol 81 (2002) 1-4
12. Bush R.K., and Portnoy J.M. The role and abatement of fungal allergens in allergic diseases. J Allergy Clin Immunol 107 3 Suppl (2001) S430-S440
13. Kurup V., Shen H.D., and Vijay H. Immunobiology of fungal allergens. Int Arch Allergy Immunol 129 (2002) 181-188
14. Gorny R.L., Reponen T., Willeke K., Schechel D., Robine E., Bossier M., et al. Fungal fragments as indoor air contaminants. Appl Environ Microbiol 68 (2002) 3522-3531
15. Erkinjuntti-Pekkanen R., Reiman M., Kokkarinen J.I., Tukiainen H.O., and Terho E.O. IgG antibodies, chronic bronchitis, and pulmonary function values in farmer's lung patients and matched controls. Allergy 54 11 (1999) 1181-1187
16. Anyanwu E.C., Campbell A.W., and Vojdani A. Neurophysiological effects of chronic indoor environmental toxic mold exposure on children. ScientificWorldJournal 3 (2003) 281-290
17. Campbell A.W., Thrasher J.D., Gray M.R., and Vojdani A. Mold and mycotoxins: effects on the neurological and immune systems in humans. Adv Appl Microbiol 55 (2004) 375-406
18. Crago B.R., Gray M.R., Nelson L.A., Davis M., Arnold L., and Thrasher J.D. Psychological, neuropsychological, and electrocortical effects of mixed mold exposure. Arch Environ Health 58 8 (2003) 452-463
19. Gordon W.A., Cantor J.B., Johanning E., Charatz H.J., Ashman T.A., Breeze J.L., et al. Cognitive impairment associated with toxigenic fungal exposure: a replication and extension of previous findings. Appl Neuropsychol 11 2 (2004) 65-74
20. Baldo J.V., Ahmad L., and Ruff R. Neuropsychological performance of patients following mold exposure. Appl Neuropsychol 9 4 (2002) 193-202
21. Hurst D. Manifestation and management of mold allergies. Presented at International Symposium on Man and His Environment in Health and Disease (June 11 2005) Dallas Texas
22. Kilburn K.H. Indoor mold exposure associated with neurobehavioral and pulmonary impairment: a preliminary report. In: Kilburn K.H. (Ed). Molds and Mycotoxins (2004), Heldref Publications, Washington, D.C.
23. Fleming R.V., Walsh T.J., and Anaissie E.J. Emerging and less common fungal pathogens. Infect Dis Clin North Am 16 4 (2002) 915-933 [vi-vii]
24. Ponikau J.U., Sherris D.A., Kern E.B., Homburger H.A., Frigas E., Gaffey T.A., et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 74 9 (1999) 877-884
25. Monod M., and Borg-von Z.M. Secreted aspartic proteases as virulence factors of Candida species. Biol Chem 383 7-8 (2002) 1087-1093
26. Brostoff J., and Gamlin L. Food allergies and food intolerance: the complete guide to their identification and treatment (2000), Inner Traditions International, Rochester
27. Bralley J.A., and Lord R.S. Laboratory evaluations in molecular medicine: nutrients, toxicants, and cell regulators (2005), The Institute for Advances in Molecular Medicine, Norcross GA
28. Tuomi T., Reijula K., Johnsson T., Hemminki K., Hintikka E.L., Lindroos O., et al. Mycotoxins in crude building materials from water-damaged buildings. Appl Environ Microbiol 66 5 (2000) 1899-1904
29. Monod M., Capoccia S., Lechenne B., Zaugg C., Holdom M., and Jousson O. Secreted proteases from pathogenic fungi. Int J Med Microbiol 292 5-6 (2002) 405-419
30. Claeson A.S., Levin J.O., Blomquist G., and Sunesson A.L. Volatile metabolites from microorganisms grown on humid building materials and synthetic media. J Environ Monit 4 5 (2002) 667-672
31. Douwes J., van der Sluis B., Doekes G., van Leusden F., Wijnands L., van Strien R., et al. Fungal extracellular polysaccharides in house dust as a marker for exposure to fungi: relations with culturable fungi, reported home dampness, and respiratory symptoms. J Allergy Clin Immunol 103 3 Pt 1 (1999) 494-500
32. Nielsen K.F. Mycotoxin production by indoor molds. Fungal Genet Biol 39 (2003) 103-117
33. Engelhart S., Loock A., Skutlarek D., Sagunski H., Lommel A., Farbe M., et al. Occurrence of toxigenic Aspergillus versicolor isolates and sterigmatocystin in carpet dust from damp indoor environments. Appl Environ Microbiol 68 (2002) 3886-3890
34. Bondy G.S., and Pestka J.J. Immunomodulation by fungal toxins. J Toxicol Environ Health B Crit Rev 3 2 (2000) 109-143
35. Berek L., Petri I.B., Mesterhazy A., Teren J., and Molnar J. Effects of mycotoxins on human immune functions in vitro. Toxicol In Vitro 15 1 (2001) 25-30
36. Pfohl-Leszkowicz A., Petkova-Bocharova T., Chernozemsky I.N., and Castegnaro M. Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins. Food Addit Contam 19 3 (2002) 282-302
37. Dominguez-Malagon H., and Gaytan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol 25 6 (2001) 497-516
38. Kordula T., Banbula A., Macomson J., and Travis J. Isolation and properties of stachyrase A, a chymotrypsin-like serine proteinase from Stachybotrys chartarum. Infect Immun 70 1 (2002) 419-421
39. Bhatnagar D., Yu J., and Ehrlich K.C. Toxins of filamentous fungi. Chem Immunol 81 (2002) 167-206
40. Hymery N., Sibiril Y., and Parent-Massin D. In vitro effects of trichothecenes on human dendritic cells. Toxicol In Vitro 20 6 (2006) 899-909
41. Wannemacher Jr, RW, Wiener SL. Trichothecene mycotoxins. In: Zajtchuk R, Bellamy RF, editors. Textbook of military medicine: medical aspects of chemical and biologic warfare. Washington, DC: Office of the Surgeon General at TMM Publications, Borden Institute, Walter Reed Army Medical Center; 1997:655-77.
42. Croft W.A., Jastromski B.M., Croft A.L., and Peters H.A. Clinical confirmation of trichothecene mycotoxicosis in patient urine. J Environ Biol 23 (2002) 301-320
43. Simon T. Neurotoxicity - mold exposure versus all causes. Presented at the 21st Annual Symposium on Man and His Environment in Health and Disease, Dallas, Texas (June 19-22 2003)
44. Anyanwu E., Campbell A.W., Vojdani A., Ehiri J.E., and Akpan A.I. Biochemical changes in the serum of patients with chronic toxigenic mold exposures: a risk factor for multiple renal dysfunctions. ScientificWorldJournal 3 (2003) 1058-1064
45. Marshall L., Weir E., Abelsohn A., and Sanborn M.D. Identifying and managing adverse environmental health effects: 1. Taking an exposure history. CMAJ 166 (2002) 1049-1055
46. Marshall LM. Exposure history. In The Ontario College of Family Physicians [association website][cited 9 October 06]. Available from the internet: 2006. http://www.ocfp.on.ca/local/files/EHC/Exposure%20Hx%20Forms.pdf.
47. Pasanen A.L. A review: fungal exposure assessment in indoor environments. Indoor Air 11 (2001) 87-98
48. Gray M.R., Thrasher J.D., Crago R., Madison R.A., Arnold L., Campbell A.W., et al. Mixed mold mycotoxicosis: immunological changes in humans following exposure in water-damaged buildings. Arch Environ Health 58 7 (2003) 410-420
49. Vojdani A., Campbell A.W., Kashanian A., and Vojdani E. Antibodies against molds and mycotoxins following exposure to toxigenic fungi in a water-damaged building. Arch Environ Health 58 6 (2003) 324-336
50. Van Emon J., Reed A., Yike I., and Vesper S. ELISA measurement of Stachylysin in serum to quantify human exposures to the indoor mold Stachybotrys chartarum. J Occup Environ Med 45 (2003) 582-591
51. Iavacoli I., Brera C., Carelli G., Caputi R., Marinaccio A., and Miraglia M. External and internal dose in subjects occupationally exposed to ochratoxin A. Int Arch Occup Environ Health 75 (2002) 381-386
52. Jarvis B.B. Analysis for mycotoxins: the chemist's perspective. In: Kilburn K.H. (Ed). Molds and Mycotoxins (2004), Heldref Publications, Washington, D.C.
53. Chandrasekar P.H., and Sobel J.D. Micafungin: a new echinocandin. Clin Infect Dis 42 8 (Apr 15 2006) 1171-1178
54. Gombart A.F., Borregaard N., and Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 19 9 (Jul 2005) 1067-1077
55. Lopez-Garcia B., Lee P.H., Yamasaki K., and Gallo R.L. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125 1 (Jul 2005) 108-115
56. Genuis S.J. The chemical erosion of human health: adverse environmental exposure and in-utero pollution - determinants of congenital disorders and chronic disease. J Perinat Med 34 (2006) 185-195
57. Genuis SJ. Fielding a current idea: exploring the public health impact of electromagnetic radiation. Public Health in press, doi:10.1016/j.puhe.2007.04.008.
58. Rea W.J. Chemical sensitivity: (vol. 4): tools of diagnosis and methods of treatment (1997), Lewis Publishers, Boca Raton
59. Rogers S.A. Lipoic acid as a potential first agent for protection from mycotoxins and treatment of mycotoxicosis. Arch Environ Health 58 8 (2003) 528-532